Premium
Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor
Author(s) -
Markowitz Jordan N.,
Fancher Karen M.
Publication year - 2018
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2076
Subject(s) - cabozantinib , medicine , tyrosine kinase inhibitor , medullary thyroid cancer , adverse effect , cancer , tyrosine kinase , oncology , thyroid cancer , renal cell carcinoma , kidney cancer , clinical trial , lung cancer , cancer research , pharmacology , receptor
Cabozantinib is an oral small‐molecule multitargeted tyrosine kinase inhibitor ( TKI ) that may confer an advantage over other TKI s that target a single receptor. It was approved by the U.S. Food and Drug Administration for the treatment of both advanced renal cell carcinoma and progressive metastatic medullary thyroid cancer, and it is being investigated for a wide array of other malignancies. Rationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article. Common adverse events are reviewed, and management strategies for select adverse events are discussed. Implications for contemporary practitioners are also provided because use of this novel agent is likely to increase as more studies are completed.